Skip to main content
Top
Published in: Hepatology International 2/2024

18-06-2023 | Sarcopenia | Original Article

Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China

Authors: Xin Zeng, Zhi-Wen Shi, Jia-Jun Yu, Li-Fen Wang, Chun-Yan Sun, Yuan-Yuan Luo, Pei-Mei Shi, Yong Lin, Yue-Xiang Chen, Jia Guo, Chun-Qing Zhang, Wei-Fen Xie

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Introduction

We aimed to determine the diagnostic criteria of myosteatosis in a Chinese population and investigate the effect of skeletal muscle abnormalities on the outcomes of cirrhotic patients.

Methods

Totally 911 volunteers were recruited to determine the diagnostic criteria and impact factors of myosteatosis, and 480 cirrhotic patients were enrolled to verify the value of muscle alterations for prognosis prediction and establish new noninvasive prognostic strategies.

Results

Multivariate analysis showed age, sex, weight, waist circumference, and biceps circumference had a remarkable influence on the L3 skeletal muscle density (L3-SMD). Based on the cut-off of a mean − 1.28 × SD among adults aged < 60 years, the diagnostic criteria for myosteatosis was L3-SMD < 38.93 Hu in males and L3-SMD < 32.82 Hu in females. Myosteatosis rather than sarcopenia has a close correlation with portal hypertension. The concurrence of sarcopenia and myosteatosis not only is associated with poor liver function but also evidently reduced the overall and liver transplantation-free survival of cirrhotic patients (p < 0.001). According to the stepwise Cox regression hazard model analysis, we established nomograms including TBil, albumin, history of HE, ascites grade, sarcopenia, and myosteatosis for easily determining survival probabilities in cirrhotic patients. The AUC is 0.874 (95% CI 0.800–0.949) for 6-month survival, 0.831 (95% CI 0.764–0.898) for 1-year survival, and 0.813 (95% CI 0.756–0.871) for 2-year survival prediction, respectively.

Conclusions

This study provides evidence of the significant correlation between skeletal muscle alterations and poor outcomes of cirrhosis, and establishes valid and convenient nomograms incorporating musculoskeletal disorders for the prognostic prediction of liver cirrhosis. Further large-scale prospective studies are necessary to verify the value of the nomograms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398(10308):1359–1376CrossRefPubMed Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398(10308):1359–1376CrossRefPubMed
2.
go back to reference Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol 2019;71(1):212–221CrossRefPubMed Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol 2019;71(1):212–221CrossRefPubMed
3.
go back to reference Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16–31CrossRefPubMed Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16–31CrossRefPubMed
4.
go back to reference Nardelli S, Lattanzi B, Merli M, Farcomeni A, Gioia S, Ridola L, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. Hepatology 2019;70(5):1704–1713CrossRefPubMed Nardelli S, Lattanzi B, Merli M, Farcomeni A, Gioia S, Ridola L, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. Hepatology 2019;70(5):1704–1713CrossRefPubMed
5.
go back to reference Fayh APT, Guedes FFO, Calado GCF, Queiroz SA, Anselmo MGGB, Sousa IM. SARC-F is a predictor of longer LOS and hospital readmission in hospitalized patients after a cardiovascular event. Nutrients 2022;14(15):3154CrossRefPubMedPubMedCentral Fayh APT, Guedes FFO, Calado GCF, Queiroz SA, Anselmo MGGB, Sousa IM. SARC-F is a predictor of longer LOS and hospital readmission in hospitalized patients after a cardiovascular event. Nutrients 2022;14(15):3154CrossRefPubMedPubMedCentral
6.
go back to reference Gao Q, Hu K, Gao J, Shang Y, Mei F, Zhao L, et al. Prevalence and prognostic value of sarcopenic obesity in patients with cancer: a systematic review and meta-analysis. Nutrition 2022;101: 111704CrossRefPubMed Gao Q, Hu K, Gao J, Shang Y, Mei F, Zhao L, et al. Prevalence and prognostic value of sarcopenic obesity in patients with cancer: a systematic review and meta-analysis. Nutrition 2022;101: 111704CrossRefPubMed
7.
go back to reference Linge J, Petersson M, Forsgren MF, Sanyal AJ, Dahlqvist LO. Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study. J Cachexia Sarcopenia Muscle 2021;12(6):1513–1526CrossRefPubMedPubMedCentral Linge J, Petersson M, Forsgren MF, Sanyal AJ, Dahlqvist LO. Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study. J Cachexia Sarcopenia Muscle 2021;12(6):1513–1526CrossRefPubMedPubMedCentral
8.
go back to reference Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74(3):1611–1644CrossRefPubMed Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74(3):1611–1644CrossRefPubMed
9.
10.
go back to reference Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int 2018;12(4):377–386CrossRefPubMed Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int 2018;12(4):377–386CrossRefPubMed
11.
go back to reference Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner PT, Cheungpasitporn W, Lukens FJ, et al. Association between sarcopenia and hepatic encephalopathy: a systematic review and meta-analysis. Ann Hepatol 2020;19(3):245–250CrossRefPubMed Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner PT, Cheungpasitporn W, Lukens FJ, et al. Association between sarcopenia and hepatic encephalopathy: a systematic review and meta-analysis. Ann Hepatol 2020;19(3):245–250CrossRefPubMed
12.
go back to reference Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010;8(11):979–985CrossRefPubMed Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010;8(11):979–985CrossRefPubMed
13.
go back to reference Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol 2021;56(7):593–619CrossRefPubMedPubMedCentral Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol 2021;56(7):593–619CrossRefPubMedPubMedCentral
14.
go back to reference European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019;70(1):172–193CrossRef European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019;70(1):172–193CrossRef
15.
go back to reference Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle 2016;7(2):126–135CrossRefPubMed Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle 2016;7(2):126–135CrossRefPubMed
16.
go back to reference Lattanzi B, Nardelli S, Pigliacelli A, Di Cola S, Farcomeni A, D’Ambrosio D, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. Dig Liver Dis 2019;51(11):1508–1512CrossRefPubMed Lattanzi B, Nardelli S, Pigliacelli A, Di Cola S, Farcomeni A, D’Ambrosio D, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. Dig Liver Dis 2019;51(11):1508–1512CrossRefPubMed
17.
go back to reference Shenvi SD, Taber DJ, Hardie AD, Botstein JO, McGillicuddy JW. Assessment of magnetic resonance imaging derived fat fraction as a sensitive and reliable predictor of myosteatosis in liver transplant recipients. HPB (Oxford) 2020;22(1):102–108CrossRefPubMed Shenvi SD, Taber DJ, Hardie AD, Botstein JO, McGillicuddy JW. Assessment of magnetic resonance imaging derived fat fraction as a sensitive and reliable predictor of myosteatosis in liver transplant recipients. HPB (Oxford) 2020;22(1):102–108CrossRefPubMed
19.
go back to reference McGovern J, Dolan RD, Horgan PG, Laird BJ, McMillan DC. Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle 2021;12(6):1408–1417CrossRefPubMedPubMedCentral McGovern J, Dolan RD, Horgan PG, Laird BJ, McMillan DC. Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle 2021;12(6):1408–1417CrossRefPubMedPubMedCentral
20.
go back to reference Son SW, Song DS, Chang UI, Yang JM. Definition of sarcopenia in chronic liver disease. Life (Basel) 2021;11(4):349PubMed Son SW, Song DS, Chang UI, Yang JM. Definition of sarcopenia in chronic liver disease. Life (Basel) 2021;11(4):349PubMed
21.
go back to reference Zeng X, Shi ZW, Yu JJ, Wang LF, Luo YY, Jin SM, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicenter study in China. J Cachexia Sarcopenia Muscle 2021;12(6):1948–1958CrossRefPubMedPubMedCentral Zeng X, Shi ZW, Yu JJ, Wang LF, Luo YY, Jin SM, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicenter study in China. J Cachexia Sarcopenia Muscle 2021;12(6):1948–1958CrossRefPubMedPubMedCentral
22.
go back to reference European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406–460CrossRef European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406–460CrossRef
23.
go back to reference Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2019;27(11):846–865 Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2019;27(11):846–865
24.
go back to reference Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6(10):573–582CrossRefPubMed Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6(10):573–582CrossRefPubMed
25.
go back to reference Kim DW, Ha J, Ko Y, Kim KW, Park T, Lee J, et al. Reliability of skeletal muscle area measurement on CT with different parameters: a phantom study. Korean J Radiol 2021;22(4):624–633CrossRefPubMedPubMedCentral Kim DW, Ha J, Ko Y, Kim KW, Park T, Lee J, et al. Reliability of skeletal muscle area measurement on CT with different parameters: a phantom study. Korean J Radiol 2021;22(4):624–633CrossRefPubMedPubMedCentral
26.
go back to reference Jennen-Steinmetz C, Wellek S. A new approach to sample size calculation for reference interval studies. Stat Med 2005;24(20):3199–3212CrossRefPubMed Jennen-Steinmetz C, Wellek S. A new approach to sample size calculation for reference interval studies. Stat Med 2005;24(20):3199–3212CrossRefPubMed
27.
go back to reference Gioia S, Ridola L, Cristofaro L, Merli M, Faccioli J, Riggio O, et al. The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Liver Int 2021;41(12):2965–2973CrossRefPubMedPubMedCentral Gioia S, Ridola L, Cristofaro L, Merli M, Faccioli J, Riggio O, et al. The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Liver Int 2021;41(12):2965–2973CrossRefPubMedPubMedCentral
28.
go back to reference Ebadi M, Montano-Loza AJ. Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis. Dig Liver Dis 2019;51(11):1493–1499CrossRefPubMed Ebadi M, Montano-Loza AJ. Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis. Dig Liver Dis 2019;51(11):1493–1499CrossRefPubMed
29.
go back to reference Kim DW, Kim KW, Ko Y, Park T, Khang S, Jeong H, et al. Assessment of myosteatosis on computed tomography by automatic generation of a muscle quality map using a web-based toolkit: feasibility study. JMIR Med Inform 2020;8(10): e23049CrossRefPubMedPubMedCentral Kim DW, Kim KW, Ko Y, Park T, Khang S, Jeong H, et al. Assessment of myosteatosis on computed tomography by automatic generation of a muscle quality map using a web-based toolkit: feasibility study. JMIR Med Inform 2020;8(10): e23049CrossRefPubMedPubMedCentral
30.
go back to reference Paternostro R, Bardach C, Hofer BS, Scheiner B, Schwabl P, Asenbaum U, et al. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. Liver Int 2021;41(4):799–809CrossRefPubMed Paternostro R, Bardach C, Hofer BS, Scheiner B, Schwabl P, Asenbaum U, et al. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. Liver Int 2021;41(4):799–809CrossRefPubMed
31.
go back to reference Kang SH, Jeong WK, Baik SK, Cha SH, Kim MY. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle 2018;9(5):860–870CrossRefPubMedPubMedCentral Kang SH, Jeong WK, Baik SK, Cha SH, Kim MY. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle 2018;9(5):860–870CrossRefPubMedPubMedCentral
32.
go back to reference Ebadi M, Tsien C, Bhanji RA, Dunichand-Hoedl AR, Rider E, Motamedrad M, et al. Myosteatosis in cirrhosis: a review of diagnosis, pathophysiological mechanisms and potential interventions. Cells 2022;11(7):1216CrossRefPubMedPubMedCentral Ebadi M, Tsien C, Bhanji RA, Dunichand-Hoedl AR, Rider E, Motamedrad M, et al. Myosteatosis in cirrhosis: a review of diagnosis, pathophysiological mechanisms and potential interventions. Cells 2022;11(7):1216CrossRefPubMedPubMedCentral
34.
go back to reference van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol 2018;68:707–714CrossRefPubMed van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol 2018;68:707–714CrossRefPubMed
Metadata
Title
Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China
Authors
Xin Zeng
Zhi-Wen Shi
Jia-Jun Yu
Li-Fen Wang
Chun-Yan Sun
Yuan-Yuan Luo
Pei-Mei Shi
Yong Lin
Yue-Xiang Chen
Jia Guo
Chun-Qing Zhang
Wei-Fen Xie
Publication date
18-06-2023
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10497-x

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.